Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Новые возможности диагностики «малых» форм поражений эпителия шейки матки, ассоциированных с папилломавирусной инфекцией (обзор литературы)
Новые возможности диагностики «малых» форм поражений эпителия шейки матки, ассоциированных с папилломавирусной инфекцией (обзор литературы)
Назарова Н.М., Прилепская В.Н., Сычева Е.Г. и др. Новые возможности диагностики «малых» форм поражений эпителия шейки матки, ассоциированных с папилломавирусной инфекцией (обзор литературы). Гинекология. 2015; 17 (5): 32–36.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В обзоре рассмотрена роль высокоонкогенных типов вируса папилломы человека (ВПЧ) в развитии поражений эпителия шейки матки. Представлены современные данные о роли молекулярно-генетических методов исследования в диагностике ВПЧ-ассоциированных заболеваний. Анализируется литература о современных молекулярных биомаркерах, которые отражают риск развития пролиферативных процессов с переходом в неоплазии.
Ключевые слова: вирус папилломы человека, цервикальные интраэпителиальные неоплазии, шейка матки, молекулярно-генетические маркеры, мРНК Е6/Е7.
Key words: human papillomavirus, cervical intraepithelial neoplasia, cervix, molecular genetic markers, E6/E7 mRNA.
Ключевые слова: вирус папилломы человека, цервикальные интраэпителиальные неоплазии, шейка матки, молекулярно-генетические маркеры, мРНК Е6/Е7.
________________________________________________
Key words: human papillomavirus, cervical intraepithelial neoplasia, cervix, molecular genetic markers, E6/E7 mRNA.
Полный текст
Список литературы
1. Золотоверхая Е.А. Молекулярные маркеры онкогенной активности вируса папилломы человека: Автореф. дис. ... канд. мед. наук. СПб, 2009. / Zolotoverkhaia E.A. Molekuliarnye markery onkogennoi aktivnosti virusa papillomy cheloveka: Avtoref. dis. ... kand. med. nauk. SPb, 2009. [in Russian]
2. Lehtinen M. Интеграция вакцины против вирусов папилломы человека в национальные программы иммунизации. Европейский журн. по секс. и репрод. здоровью. 2007; 64: 12. / Lehtinen M. Integratsiia vaktsiny protiv virusov papillomy cheloveka v natsional'nye programmy immunizatsii. Evropeiskii zhurn. po seks. i reprod. zdorov'iu. 2007; 64: 12. [in Russian]
3. Waxman AG, Chelmow D, Darragh TM et al. Revised Terminology for Cervical Histopathology and Its Implications for Management of High-Grade Squamous Intraepithelial Lesions of the Cervix. Obstet Gynecol 2012; 120 (6): 1465–71.
4. Doorbar J, Egawa N, Griffin H. Human papillomavirus molecular biology and disease association. Rev Med Virol 2015; 25: 2–23.
5. Cricca M, Morselli-Labate AM, Venturoli S et al. Viral DNA load, physical status and E2/E6 ratio as markers to grade HPV16 positive women for high-grade cervical lesions. Gynecol Oncol Res 2007; 106 (3): 49–57.
6. Lethaby A, Brown J, Marjoribanks et al. Phytoestrogens for vasomotor menopausal symptoms. Cochran Database Syst Rev 2007: CD001395
7. Куевда Д.А., Шипулина О.Ю. Генодиагностика папилломавирусной инфекции высокого канцерогенного риска. Количественный подход. Патология шейки матки и генитальная инфекция. Т. 3. М., 2007; c. 108–19. / Kuevda D.A., Shipulina O.Iu. Genodiagnostika papillomavirusnoi infektsii vysokogo kantserogennogo riska. Kolichestvennyi podkhod. Patologiia sheiki matki i genital'naia infektsiia. T. 3. M., 2007; c. 108–19. [in Russian]
8. Kapeu AS, Luostarinen T, Jellum E et al. Is Smoking an Independent Risk Factor for Invasive Cervical Cancer? A Nested Case-Control Study Within Nordic Biobanks. Am J Epidemiol 2009; 169 (4): 480–8.
9. Sørbye SW, Fismen S, Gutteberg TJ et al. Triage of women with minor cervical lesions: data suggesting a "test and treat" approach for HPV E6/E7 mRNA testing. PLoS One 2010; 5 (9): e12724.
10. Ghittoni R, Accardi R, Chiocca S et al. Role of human papillomaviruses in carcinogenesis. ecancer 2015, 9: 526.
11. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2 (5): 342–50.
12. Bosch FX et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group [see comments] J Natl Cancer Inst 1995; 87 (11): 796–802.
13. Munoz N et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348 (6): 518–27.
14. De Sanjose S et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective crosssectional worldwide study. Lancet Oncol 2010; 11 (11): 1048–56.
15. Smith JS et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update Int J Cancer 2007; 121 (3): 621–32.
16. von Knebel-Döberitz M, Syrjänen K. Molecular markers. How to apply in practice. Gynecol Oncol 2006; 103: 18–20.
17. Szoke K, Sapy T, Krasznai Z et al. Moderate variation of the oncogenic potential among high-risk human papillomavirus types in gynecologic patients with cervical abnormalities. J Med Virol 2003; 71: 585–92.
18. Molano M, van den Brulel A, Plummer M et al. Determinants of Clearance of Human Papillomavirus Infections in Colombian Women with Normal Cytology: A Population-based, 5-Year Follow-up Study. Am J Epidemiol 2003; 158 (5): 486–94.
19. Schneider A et al. Screening for cervical intraepithelial neoplasia grade 2/3: validity of cytologic study, cervicography, and human papillomavirus detection. Am J Obstet Gynecol 1996; 174 (5): 1534–41.
20. Grce M, Davies P. Human papillomavirus testing for primary cervical cancer screening. Expert Rev Mol Diagn 2008; 8 (5): 599–605.
21. Mandelblatt JS, Lawrence WF, Womack SM et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002; 287: 2372–81.
22. Naucler P, Ryd W, Törnberg S et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589–97.
23. Schiffman M, Wentzensen N. From Human papillomavirus to cervical cancer. Obstet Gynecol 2010; 116 (1): 177–85.
24. Sorbye SW, Fismen S, Gutteberg TJ et al. HPV mRNA test in women with minor cervical lesions: experience of the University Hospital of North Norway. J Virol Methods 2010; 169: 219–2.
25. Tropé A, Sjoborg K, Eskild A et al. Performance of Human Papillomavirus DNA and mRNA Testing Strategies for Women with and without Cervical Neoplasia. J Clin Microbiol 2009; 47 (8): 2458–64.
26. Castle PE, Fetterman B, Poitras N et al. Variable risk of cervical precancer and cancer after a human papillomavirus-positive test. Obstet Gynecol 2011; V (117); 650–6.
27. Ho GY, Bierman R, Beardsley L et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423–28.
28. Sankaranarayanan R et al. HPV screening for cervical cancer in rural India N Engl J Med 2009; 360 (14): 1385–94.
29. Tropé A, Sjoborg KD, Nygård M et al. Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds. J Clin Microbiol 2012; 50 (6): 1927–35.
30. Ronco G, Cuzick J, Pierotti P et al. Accuracy of liquid versus conventional cytology: overall results of new technologies for cervical cancer screening: randomized controlled trial. BMJ 2007; 335 (7609): 28.
31. Moore EE, Danielewski JA, Garland SM et al. Clearance of human papillomavirus in women treated for cervical dysplasia. Obstet Gynecol 2011; 117: 101–8.
32. Серов В.Н., Баранов И.И. Лечение урогенитальных инфекций у женщин в современных условиях. Рус. мед. журн. 2004; 12 (8): 564–9.
33. Шабалова И.П., Касоян К.Т. Цитологическая диагностика заболеваний шейки матки и тела матки. 3-е изд., испр. и доп. М.: Триада, 2010. / Shabalova I.P., Kasoian K.T. Tsitologicheskaia diagnostika zabolevanii sheiki matki i tela matki. 3-e izd., ispr. i dop. M.: Triada, 2010. [in Russian]
34. Ronco G, Cuzick J, Pierotti P et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening randomized controlled trial. BMJ 2007; 5 (7609): 28–38.
35. Роговская С.И. Папилломавирусная инфекция у женщин и патология шейки матки: в помощь практикующему врачу. М.: ГЭОТАР-Медиа, 2005; 39–42. / Rogovskaia S.I. Papillomavirusnaia infektsiia u zhenshchin i patologiia sheiki matki: v pomoshch' praktikuiushchemu vrachu. M.: GEOTAR-Media, 2005; 39–42. [in Russian]
36. Троицкая О.Г. Современные методы диагностики и лечения папилломавирусной инфекции шейки матки у женщин репродуктивного возраста. Автореф. дис. … канд. мед. наук. СПб., 2008. / Troitskaia O.G. Sovremennye metody diagnostiki i lecheniia papillomavirusnoi infektsii sheiki matki u zhenshchin reproduktivnogo vozrasta. Avtoref. dis. … kand. med. nauk. SPb., 2008. [in Russian]
37. Arbyn M, Martin-Hirsch P, Buntinx F et al. Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate. J Cell Mol Med 2009; 13: 648–59.
38. Koliopoulos G, Arbyn M, Martin-Hirsch P et al. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol 2007; 104 (1): 232–46.
39. Сухих Г.Т., Прилепская В.Н. Профилактика рака шейки матки. М.: МЕДпресс-информ, 2012; с. 25–30. / Sukhikh G.T., Prilepskaia V.N. Profilaktika raka sheiki matki. M.: MEDpress-inform, 2012; s. 25–30. [in Russian]
40. Роговская С.И., Подзолкова Н.М., Минкина Г.Н. Новое в кольпоскопии. Гинекология. 2011; 13 (5): 62–6. / Rogovskaia S.I., Podzolkova N.M., Minkina G.N. Novoe v kol'poskopii. Ginekology. 2011; 13 (5): 62–6. [in Russian]
41. Saslow D, Castle PE, Cox JT et al. American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors. C A Cancer J Clin 2007; 57: 7–28.
42. Wentzensen N, Sherman ME, Schiffman M et al. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecologic Oncology 2009; 112 (2): 293–9.
43. Nasioutziki M, Daniilidis A, Dinas K et al. The evaluation of p16INK4a immunoexpression/immunostaining and human papillomavirus DNA test in cervical liquid-based cytological samples. Int J Gynecol Cancer 2011; 21 (1): 79–85.
44. Sørbye SW, Fismen S, Gutteberg TJ et al. HPV mRNA Is More Specific than HPV DNA in Triage of Women with Minor Cervical Lesions. PLoS One 2014; 9 (1).
45. Wang F, Li Y, Zhou J et al. miR-375 is down-regulated in squa-mous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1. Am J Pathol 2011; 179: 2580–8.
46. Caraceni D, Ghiringhello B, Keller T et al. p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol 2011; 119 (3): 158–66.
47. Possati-Resende JC, Fregnani JH, Kerr LM et al. The Accuracy of p16/Ki-67 and HPV Test in the Detection of CIN2/3 in Women Diagnosed with ASC-US or LSIL. PLoS One 2015; 10 (7).
48. Heng ZM, Wang X. Regulation of cellular miRNA expression by human papillomaviruses. Biochim Biophys Acta 2011; 1809 (11–12): 668–77.
49. Molden T, Nygård JF, Kraus I et al. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-Proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear. Int J Cancer 2005; 114 (6): 973–6.
50. Cuzick J, Cadman L, Mesher D et al. Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer 2013; 108: 908–13.
51. Cattani P, Zannoni GF, Ricci C et al. Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. J Clin Microbiol 2009; 47: 3895–01.
2. Lehtinen M. Integratsiia vaktsiny protiv virusov papillomy cheloveka v natsional'nye programmy immunizatsii. Evropeiskii zhurn. po seks. i reprod. zdorov'iu. 2007; 64: 12. [in Russian]
3. Waxman AG, Chelmow D, Darragh TM et al. Revised Terminology for Cervical Histopathology and Its Implications for Management of High-Grade Squamous Intraepithelial Lesions of the Cervix. Obstet Gynecol 2012; 120 (6): 1465–71.
4. Doorbar J, Egawa N, Griffin H. Human papillomavirus molecular biology and disease association. Rev Med Virol 2015; 25: 2–23.
5. Cricca M, Morselli-Labate AM, Venturoli S et al. Viral DNA load, physical status and E2/E6 ratio as markers to grade HPV16 positive women for high-grade cervical lesions. Gynecol Oncol Res 2007; 106 (3): 49–57.
6. Lethaby A, Brown J, Marjoribanks et al. Phytoestrogens for vasomotor menopausal symptoms. Cochran Database Syst Rev 2007: CD001395
7. Kuevda D.A., Shipulina O.Iu. Genodiagnostika papillomavirusnoi infektsii vysokogo kantserogennogo riska. Kolichestvennyi podkhod. Patologiia sheiki matki i genital'naia infektsiia. T. 3. M., 2007; c. 108–19. [in Russian]
8. Kapeu AS, Luostarinen T, Jellum E et al. Is Smoking an Independent Risk Factor for Invasive Cervical Cancer? A Nested Case-Control Study Within Nordic Biobanks. Am J Epidemiol 2009; 169 (4): 480–8.
9. Sørbye SW, Fismen S, Gutteberg TJ et al. Triage of women with minor cervical lesions: data suggesting a "test and treat" approach for HPV E6/E7 mRNA testing. PLoS One 2010; 5 (9): e12724.
10. Ghittoni R, Accardi R, Chiocca S et al. Role of human papillomaviruses in carcinogenesis. ecancer 2015, 9: 526.
11. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2 (5): 342–50.
12. Bosch FX et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group [see comments] J Natl Cancer Inst 1995; 87 (11): 796–802.
13. Munoz N et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348 (6): 518–27.
14. De Sanjose S et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective crosssectional worldwide study. Lancet Oncol 2010; 11 (11): 1048–56.
15. Smith JS et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update Int J Cancer 2007; 121 (3): 621–32.
16. von Knebel-Döberitz M, Syrjänen K. Molecular markers. How to apply in practice. Gynecol Oncol 2006; 103: 18–20.
17. Szoke K, Sapy T, Krasznai Z et al. Moderate variation of the oncogenic potential among high-risk human papillomavirus types in gynecologic patients with cervical abnormalities. J Med Virol 2003; 71: 585–92.
18. Molano M, van den Brulel A, Plummer M et al. Determinants of Clearance of Human Papillomavirus Infections in Colombian Women with Normal Cytology: A Population-based, 5-Year Follow-up Study. Am J Epidemiol 2003; 158 (5): 486–94.
19. Schneider A et al. Screening for cervical intraepithelial neoplasia grade 2/3: validity of cytologic study, cervicography, and human papillomavirus detection. Am J Obstet Gynecol 1996; 174 (5): 1534–41.
20. Grce M, Davies P. Human papillomavirus testing for primary cervical cancer screening. Expert Rev Mol Diagn 2008; 8 (5): 599–605.
21. Mandelblatt JS, Lawrence WF, Womack SM et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002; 287: 2372–81.
22. Naucler P, Ryd W, Törnberg S et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589–97.
23. Schiffman M, Wentzensen N. From Human papillomavirus to cervical cancer. Obstet Gynecol 2010; 116 (1): 177–85.
24. Sorbye SW, Fismen S, Gutteberg TJ et al. HPV mRNA test in women with minor cervical lesions: experience of the University Hospital of North Norway. J Virol Methods 2010; 169: 219–2.
25. Tropé A, Sjoborg K, Eskild A et al. Performance of Human Papillomavirus DNA and mRNA Testing Strategies for Women with and without Cervical Neoplasia. J Clin Microbiol 2009; 47 (8): 2458–64.
26. Castle PE, Fetterman B, Poitras N et al. Variable risk of cervical precancer and cancer after a human papillomavirus-positive test. Obstet Gynecol 2011; V (117); 650–6.
27. Ho GY, Bierman R, Beardsley L et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423–28.
28. Sankaranarayanan R et al. HPV screening for cervical cancer in rural India N Engl J Med 2009; 360 (14): 1385–94.
29. Tropé A, Sjoborg KD, Nygård M et al. Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds. J Clin Microbiol 2012; 50 (6): 1927–35.
30. Ronco G, Cuzick J, Pierotti P et al. Accuracy of liquid versus conventional cytology: overall results of new technologies for cervical cancer screening: randomized controlled trial. BMJ 2007; 335 (7609): 28.
31. Moore EE, Danielewski JA, Garland SM et al. Clearance of human papillomavirus in women treated for cervical dysplasia. Obstet Gynecol 2011; 117: 101–8.
32. Серов В.Н., Баранов И.И. Лечение урогенитальных инфекций у женщин в современных условиях. Рус. мед. журн. 2004; 12 (8): 564–9.
33. Shabalova I.P., Kasoian K.T. Tsitologicheskaia diagnostika zabolevanii sheiki matki i tela matki. 3-e izd., ispr. i dop. M.: Triada, 2010. [in Russian]
34. Ronco G, Cuzick J, Pierotti P et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening randomized controlled trial. BMJ 2007; 5 (7609): 28–38.
35. Rogovskaia S.I. Papillomavirusnaia infektsiia u zhenshchin i patologiia sheiki matki: v pomoshch' praktikuiushchemu vrachu. M.: GEOTAR-Media, 2005; 39–42. [in Russian]
36. Troitskaia O.G. Sovremennye metody diagnostiki i lecheniia papillomavirusnoi infektsii sheiki matki u zhenshchin reproduktivnogo vozrasta. Avtoref. dis. … kand. med. nauk. SPb., 2008. [in Russian]
37. Arbyn M, Martin-Hirsch P, Buntinx F et al. Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate. J Cell Mol Med 2009; 13: 648–59.
38. Koliopoulos G, Arbyn M, Martin-Hirsch P et al. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol 2007; 104 (1): 232–46.
39. Sukhikh G.T., Prilepskaia V.N. Profilaktika raka sheiki matki. M.: MEDpress-inform, 2012; s. 25–30. [in Russian]
40. Rogovskaia S.I., Podzolkova N.M., Minkina G.N. Novoe v kol'poskopii. Ginekology. 2011; 13 (5): 62–6. [in Russian]
41. Saslow D, Castle PE, Cox JT et al. American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors. C A Cancer J Clin 2007; 57: 7–28.
42. Wentzensen N, Sherman ME, Schiffman M et al. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecologic Oncology 2009; 112 (2): 293–9.
43. Nasioutziki M, Daniilidis A, Dinas K et al. The evaluation of p16INK4a immunoexpression/immunostaining and human papillomavirus DNA test in cervical liquid-based cytological samples. Int J Gynecol Cancer 2011; 21 (1): 79–85.
44. Sørbye SW, Fismen S, Gutteberg TJ et al. HPV mRNA Is More Specific than HPV DNA in Triage of Women with Minor Cervical Lesions. PLoS One 2014; 9 (1).
45. Wang F, Li Y, Zhou J et al. miR-375 is down-regulated in squa-mous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1. Am J Pathol 2011; 179: 2580–8.
46. Caraceni D, Ghiringhello B, Keller T et al. p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol 2011; 119 (3): 158–66.
47. Possati-Resende JC, Fregnani JH, Kerr LM et al. The Accuracy of p16/Ki-67 and HPV Test in the Detection of CIN2/3 in Women Diagnosed with ASC-US or LSIL. PLoS One 2015; 10 (7).
48. Heng ZM, Wang X. Regulation of cellular miRNA expression by human papillomaviruses. Biochim Biophys Acta 2011; 1809 (11–12): 668–77.
49. Molden T, Nygård JF, Kraus I et al. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-Proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear. Int J Cancer 2005; 114 (6): 973–6.
50. Cuzick J, Cadman L, Mesher D et al. Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer 2013; 108: 908–13.
51. Cattani P, Zannoni GF, Ricci C et al. Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. J Clin Microbiol 2009; 47: 3895–01.
2. Lehtinen M. Интеграция вакцины против вирусов папилломы человека в национальные программы иммунизации. Европейский журн. по секс. и репрод. здоровью. 2007; 64: 12. / Lehtinen M. Integratsiia vaktsiny protiv virusov papillomy cheloveka v natsional'nye programmy immunizatsii. Evropeiskii zhurn. po seks. i reprod. zdorov'iu. 2007; 64: 12. [in Russian]
3. Waxman AG, Chelmow D, Darragh TM et al. Revised Terminology for Cervical Histopathology and Its Implications for Management of High-Grade Squamous Intraepithelial Lesions of the Cervix. Obstet Gynecol 2012; 120 (6): 1465–71.
4. Doorbar J, Egawa N, Griffin H. Human papillomavirus molecular biology and disease association. Rev Med Virol 2015; 25: 2–23.
5. Cricca M, Morselli-Labate AM, Venturoli S et al. Viral DNA load, physical status and E2/E6 ratio as markers to grade HPV16 positive women for high-grade cervical lesions. Gynecol Oncol Res 2007; 106 (3): 49–57.
6. Lethaby A, Brown J, Marjoribanks et al. Phytoestrogens for vasomotor menopausal symptoms. Cochran Database Syst Rev 2007: CD001395
7. Куевда Д.А., Шипулина О.Ю. Генодиагностика папилломавирусной инфекции высокого канцерогенного риска. Количественный подход. Патология шейки матки и генитальная инфекция. Т. 3. М., 2007; c. 108–19. / Kuevda D.A., Shipulina O.Iu. Genodiagnostika papillomavirusnoi infektsii vysokogo kantserogennogo riska. Kolichestvennyi podkhod. Patologiia sheiki matki i genital'naia infektsiia. T. 3. M., 2007; c. 108–19. [in Russian]
8. Kapeu AS, Luostarinen T, Jellum E et al. Is Smoking an Independent Risk Factor for Invasive Cervical Cancer? A Nested Case-Control Study Within Nordic Biobanks. Am J Epidemiol 2009; 169 (4): 480–8.
9. Sørbye SW, Fismen S, Gutteberg TJ et al. Triage of women with minor cervical lesions: data suggesting a "test and treat" approach for HPV E6/E7 mRNA testing. PLoS One 2010; 5 (9): e12724.
10. Ghittoni R, Accardi R, Chiocca S et al. Role of human papillomaviruses in carcinogenesis. ecancer 2015, 9: 526.
11. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2 (5): 342–50.
12. Bosch FX et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group [see comments] J Natl Cancer Inst 1995; 87 (11): 796–802.
13. Munoz N et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348 (6): 518–27.
14. De Sanjose S et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective crosssectional worldwide study. Lancet Oncol 2010; 11 (11): 1048–56.
15. Smith JS et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update Int J Cancer 2007; 121 (3): 621–32.
16. von Knebel-Döberitz M, Syrjänen K. Molecular markers. How to apply in practice. Gynecol Oncol 2006; 103: 18–20.
17. Szoke K, Sapy T, Krasznai Z et al. Moderate variation of the oncogenic potential among high-risk human papillomavirus types in gynecologic patients with cervical abnormalities. J Med Virol 2003; 71: 585–92.
18. Molano M, van den Brulel A, Plummer M et al. Determinants of Clearance of Human Papillomavirus Infections in Colombian Women with Normal Cytology: A Population-based, 5-Year Follow-up Study. Am J Epidemiol 2003; 158 (5): 486–94.
19. Schneider A et al. Screening for cervical intraepithelial neoplasia grade 2/3: validity of cytologic study, cervicography, and human papillomavirus detection. Am J Obstet Gynecol 1996; 174 (5): 1534–41.
20. Grce M, Davies P. Human papillomavirus testing for primary cervical cancer screening. Expert Rev Mol Diagn 2008; 8 (5): 599–605.
21. Mandelblatt JS, Lawrence WF, Womack SM et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002; 287: 2372–81.
22. Naucler P, Ryd W, Törnberg S et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589–97.
23. Schiffman M, Wentzensen N. From Human papillomavirus to cervical cancer. Obstet Gynecol 2010; 116 (1): 177–85.
24. Sorbye SW, Fismen S, Gutteberg TJ et al. HPV mRNA test in women with minor cervical lesions: experience of the University Hospital of North Norway. J Virol Methods 2010; 169: 219–2.
25. Tropé A, Sjoborg K, Eskild A et al. Performance of Human Papillomavirus DNA and mRNA Testing Strategies for Women with and without Cervical Neoplasia. J Clin Microbiol 2009; 47 (8): 2458–64.
26. Castle PE, Fetterman B, Poitras N et al. Variable risk of cervical precancer and cancer after a human papillomavirus-positive test. Obstet Gynecol 2011; V (117); 650–6.
27. Ho GY, Bierman R, Beardsley L et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423–28.
28. Sankaranarayanan R et al. HPV screening for cervical cancer in rural India N Engl J Med 2009; 360 (14): 1385–94.
29. Tropé A, Sjoborg KD, Nygård M et al. Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds. J Clin Microbiol 2012; 50 (6): 1927–35.
30. Ronco G, Cuzick J, Pierotti P et al. Accuracy of liquid versus conventional cytology: overall results of new technologies for cervical cancer screening: randomized controlled trial. BMJ 2007; 335 (7609): 28.
31. Moore EE, Danielewski JA, Garland SM et al. Clearance of human papillomavirus in women treated for cervical dysplasia. Obstet Gynecol 2011; 117: 101–8.
32. Серов В.Н., Баранов И.И. Лечение урогенитальных инфекций у женщин в современных условиях. Рус. мед. журн. 2004; 12 (8): 564–9.
33. Шабалова И.П., Касоян К.Т. Цитологическая диагностика заболеваний шейки матки и тела матки. 3-е изд., испр. и доп. М.: Триада, 2010. / Shabalova I.P., Kasoian K.T. Tsitologicheskaia diagnostika zabolevanii sheiki matki i tela matki. 3-e izd., ispr. i dop. M.: Triada, 2010. [in Russian]
34. Ronco G, Cuzick J, Pierotti P et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening randomized controlled trial. BMJ 2007; 5 (7609): 28–38.
35. Роговская С.И. Папилломавирусная инфекция у женщин и патология шейки матки: в помощь практикующему врачу. М.: ГЭОТАР-Медиа, 2005; 39–42. / Rogovskaia S.I. Papillomavirusnaia infektsiia u zhenshchin i patologiia sheiki matki: v pomoshch' praktikuiushchemu vrachu. M.: GEOTAR-Media, 2005; 39–42. [in Russian]
36. Троицкая О.Г. Современные методы диагностики и лечения папилломавирусной инфекции шейки матки у женщин репродуктивного возраста. Автореф. дис. … канд. мед. наук. СПб., 2008. / Troitskaia O.G. Sovremennye metody diagnostiki i lecheniia papillomavirusnoi infektsii sheiki matki u zhenshchin reproduktivnogo vozrasta. Avtoref. dis. … kand. med. nauk. SPb., 2008. [in Russian]
37. Arbyn M, Martin-Hirsch P, Buntinx F et al. Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate. J Cell Mol Med 2009; 13: 648–59.
38. Koliopoulos G, Arbyn M, Martin-Hirsch P et al. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol 2007; 104 (1): 232–46.
39. Сухих Г.Т., Прилепская В.Н. Профилактика рака шейки матки. М.: МЕДпресс-информ, 2012; с. 25–30. / Sukhikh G.T., Prilepskaia V.N. Profilaktika raka sheiki matki. M.: MEDpress-inform, 2012; s. 25–30. [in Russian]
40. Роговская С.И., Подзолкова Н.М., Минкина Г.Н. Новое в кольпоскопии. Гинекология. 2011; 13 (5): 62–6. / Rogovskaia S.I., Podzolkova N.M., Minkina G.N. Novoe v kol'poskopii. Ginekology. 2011; 13 (5): 62–6. [in Russian]
41. Saslow D, Castle PE, Cox JT et al. American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors. C A Cancer J Clin 2007; 57: 7–28.
42. Wentzensen N, Sherman ME, Schiffman M et al. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecologic Oncology 2009; 112 (2): 293–9.
43. Nasioutziki M, Daniilidis A, Dinas K et al. The evaluation of p16INK4a immunoexpression/immunostaining and human papillomavirus DNA test in cervical liquid-based cytological samples. Int J Gynecol Cancer 2011; 21 (1): 79–85.
44. Sørbye SW, Fismen S, Gutteberg TJ et al. HPV mRNA Is More Specific than HPV DNA in Triage of Women with Minor Cervical Lesions. PLoS One 2014; 9 (1).
45. Wang F, Li Y, Zhou J et al. miR-375 is down-regulated in squa-mous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1. Am J Pathol 2011; 179: 2580–8.
46. Caraceni D, Ghiringhello B, Keller T et al. p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol 2011; 119 (3): 158–66.
47. Possati-Resende JC, Fregnani JH, Kerr LM et al. The Accuracy of p16/Ki-67 and HPV Test in the Detection of CIN2/3 in Women Diagnosed with ASC-US or LSIL. PLoS One 2015; 10 (7).
48. Heng ZM, Wang X. Regulation of cellular miRNA expression by human papillomaviruses. Biochim Biophys Acta 2011; 1809 (11–12): 668–77.
49. Molden T, Nygård JF, Kraus I et al. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-Proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear. Int J Cancer 2005; 114 (6): 973–6.
50. Cuzick J, Cadman L, Mesher D et al. Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer 2013; 108: 908–13.
51. Cattani P, Zannoni GF, Ricci C et al. Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. J Clin Microbiol 2009; 47: 3895–01.
________________________________________________
2. Lehtinen M. Integratsiia vaktsiny protiv virusov papillomy cheloveka v natsional'nye programmy immunizatsii. Evropeiskii zhurn. po seks. i reprod. zdorov'iu. 2007; 64: 12. [in Russian]
3. Waxman AG, Chelmow D, Darragh TM et al. Revised Terminology for Cervical Histopathology and Its Implications for Management of High-Grade Squamous Intraepithelial Lesions of the Cervix. Obstet Gynecol 2012; 120 (6): 1465–71.
4. Doorbar J, Egawa N, Griffin H. Human papillomavirus molecular biology and disease association. Rev Med Virol 2015; 25: 2–23.
5. Cricca M, Morselli-Labate AM, Venturoli S et al. Viral DNA load, physical status and E2/E6 ratio as markers to grade HPV16 positive women for high-grade cervical lesions. Gynecol Oncol Res 2007; 106 (3): 49–57.
6. Lethaby A, Brown J, Marjoribanks et al. Phytoestrogens for vasomotor menopausal symptoms. Cochran Database Syst Rev 2007: CD001395
7. Kuevda D.A., Shipulina O.Iu. Genodiagnostika papillomavirusnoi infektsii vysokogo kantserogennogo riska. Kolichestvennyi podkhod. Patologiia sheiki matki i genital'naia infektsiia. T. 3. M., 2007; c. 108–19. [in Russian]
8. Kapeu AS, Luostarinen T, Jellum E et al. Is Smoking an Independent Risk Factor for Invasive Cervical Cancer? A Nested Case-Control Study Within Nordic Biobanks. Am J Epidemiol 2009; 169 (4): 480–8.
9. Sørbye SW, Fismen S, Gutteberg TJ et al. Triage of women with minor cervical lesions: data suggesting a "test and treat" approach for HPV E6/E7 mRNA testing. PLoS One 2010; 5 (9): e12724.
10. Ghittoni R, Accardi R, Chiocca S et al. Role of human papillomaviruses in carcinogenesis. ecancer 2015, 9: 526.
11. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2 (5): 342–50.
12. Bosch FX et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group [see comments] J Natl Cancer Inst 1995; 87 (11): 796–802.
13. Munoz N et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348 (6): 518–27.
14. De Sanjose S et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective crosssectional worldwide study. Lancet Oncol 2010; 11 (11): 1048–56.
15. Smith JS et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update Int J Cancer 2007; 121 (3): 621–32.
16. von Knebel-Döberitz M, Syrjänen K. Molecular markers. How to apply in practice. Gynecol Oncol 2006; 103: 18–20.
17. Szoke K, Sapy T, Krasznai Z et al. Moderate variation of the oncogenic potential among high-risk human papillomavirus types in gynecologic patients with cervical abnormalities. J Med Virol 2003; 71: 585–92.
18. Molano M, van den Brulel A, Plummer M et al. Determinants of Clearance of Human Papillomavirus Infections in Colombian Women with Normal Cytology: A Population-based, 5-Year Follow-up Study. Am J Epidemiol 2003; 158 (5): 486–94.
19. Schneider A et al. Screening for cervical intraepithelial neoplasia grade 2/3: validity of cytologic study, cervicography, and human papillomavirus detection. Am J Obstet Gynecol 1996; 174 (5): 1534–41.
20. Grce M, Davies P. Human papillomavirus testing for primary cervical cancer screening. Expert Rev Mol Diagn 2008; 8 (5): 599–605.
21. Mandelblatt JS, Lawrence WF, Womack SM et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002; 287: 2372–81.
22. Naucler P, Ryd W, Törnberg S et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589–97.
23. Schiffman M, Wentzensen N. From Human papillomavirus to cervical cancer. Obstet Gynecol 2010; 116 (1): 177–85.
24. Sorbye SW, Fismen S, Gutteberg TJ et al. HPV mRNA test in women with minor cervical lesions: experience of the University Hospital of North Norway. J Virol Methods 2010; 169: 219–2.
25. Tropé A, Sjoborg K, Eskild A et al. Performance of Human Papillomavirus DNA and mRNA Testing Strategies for Women with and without Cervical Neoplasia. J Clin Microbiol 2009; 47 (8): 2458–64.
26. Castle PE, Fetterman B, Poitras N et al. Variable risk of cervical precancer and cancer after a human papillomavirus-positive test. Obstet Gynecol 2011; V (117); 650–6.
27. Ho GY, Bierman R, Beardsley L et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423–28.
28. Sankaranarayanan R et al. HPV screening for cervical cancer in rural India N Engl J Med 2009; 360 (14): 1385–94.
29. Tropé A, Sjoborg KD, Nygård M et al. Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds. J Clin Microbiol 2012; 50 (6): 1927–35.
30. Ronco G, Cuzick J, Pierotti P et al. Accuracy of liquid versus conventional cytology: overall results of new technologies for cervical cancer screening: randomized controlled trial. BMJ 2007; 335 (7609): 28.
31. Moore EE, Danielewski JA, Garland SM et al. Clearance of human papillomavirus in women treated for cervical dysplasia. Obstet Gynecol 2011; 117: 101–8.
32. Серов В.Н., Баранов И.И. Лечение урогенитальных инфекций у женщин в современных условиях. Рус. мед. журн. 2004; 12 (8): 564–9.
33. Shabalova I.P., Kasoian K.T. Tsitologicheskaia diagnostika zabolevanii sheiki matki i tela matki. 3-e izd., ispr. i dop. M.: Triada, 2010. [in Russian]
34. Ronco G, Cuzick J, Pierotti P et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening randomized controlled trial. BMJ 2007; 5 (7609): 28–38.
35. Rogovskaia S.I. Papillomavirusnaia infektsiia u zhenshchin i patologiia sheiki matki: v pomoshch' praktikuiushchemu vrachu. M.: GEOTAR-Media, 2005; 39–42. [in Russian]
36. Troitskaia O.G. Sovremennye metody diagnostiki i lecheniia papillomavirusnoi infektsii sheiki matki u zhenshchin reproduktivnogo vozrasta. Avtoref. dis. … kand. med. nauk. SPb., 2008. [in Russian]
37. Arbyn M, Martin-Hirsch P, Buntinx F et al. Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate. J Cell Mol Med 2009; 13: 648–59.
38. Koliopoulos G, Arbyn M, Martin-Hirsch P et al. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol 2007; 104 (1): 232–46.
39. Sukhikh G.T., Prilepskaia V.N. Profilaktika raka sheiki matki. M.: MEDpress-inform, 2012; s. 25–30. [in Russian]
40. Rogovskaia S.I., Podzolkova N.M., Minkina G.N. Novoe v kol'poskopii. Ginekology. 2011; 13 (5): 62–6. [in Russian]
41. Saslow D, Castle PE, Cox JT et al. American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors. C A Cancer J Clin 2007; 57: 7–28.
42. Wentzensen N, Sherman ME, Schiffman M et al. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecologic Oncology 2009; 112 (2): 293–9.
43. Nasioutziki M, Daniilidis A, Dinas K et al. The evaluation of p16INK4a immunoexpression/immunostaining and human papillomavirus DNA test in cervical liquid-based cytological samples. Int J Gynecol Cancer 2011; 21 (1): 79–85.
44. Sørbye SW, Fismen S, Gutteberg TJ et al. HPV mRNA Is More Specific than HPV DNA in Triage of Women with Minor Cervical Lesions. PLoS One 2014; 9 (1).
45. Wang F, Li Y, Zhou J et al. miR-375 is down-regulated in squa-mous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1. Am J Pathol 2011; 179: 2580–8.
46. Caraceni D, Ghiringhello B, Keller T et al. p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol 2011; 119 (3): 158–66.
47. Possati-Resende JC, Fregnani JH, Kerr LM et al. The Accuracy of p16/Ki-67 and HPV Test in the Detection of CIN2/3 in Women Diagnosed with ASC-US or LSIL. PLoS One 2015; 10 (7).
48. Heng ZM, Wang X. Regulation of cellular miRNA expression by human papillomaviruses. Biochim Biophys Acta 2011; 1809 (11–12): 668–77.
49. Molden T, Nygård JF, Kraus I et al. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-Proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear. Int J Cancer 2005; 114 (6): 973–6.
50. Cuzick J, Cadman L, Mesher D et al. Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer 2013; 108: 908–13.
51. Cattani P, Zannoni GF, Ricci C et al. Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. J Clin Microbiol 2009; 47: 3895–01.
Авторы
Н.М.Назарова, В.Н.Прилепская*, Е.Г.Сычева, М.Д.Зардиашвили, О.В.Бурменская
ФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова Минздрава России. 117997, Россия, Москва, ул. Академика Опарина, д. 4
*VPrilepskaya@mail.ru
V.I.Kulakov Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation. 1179974, Russian
Federation, Moscow, ul. Akademika Oparina, d. 4
*VPrilepskaya@mail.ru
ФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова Минздрава России. 117997, Россия, Москва, ул. Академика Опарина, д. 4
*VPrilepskaya@mail.ru
________________________________________________
V.I.Kulakov Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation. 1179974, Russian
Federation, Moscow, ul. Akademika Oparina, d. 4
*VPrilepskaya@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.